Rob Dillard

DocwireNews

Iovance Biotherapeutics, a biotechnology company focused on producing tumor-infiltrating lymphocyte (TIL) therapies for cancer, has <a href="https://ir.iovance.com/node/14086/" target="_blank" rel="noopener">announced</a> a clinical program update for LN-145 TIL therapy in the treatment of non-small cell lung cancer (NSCLC).The US Food and Drug Administration (FDA) placed a clinical hold on the IOV-LUN-202 trial in December in response to a recently reported fatal event that was possibly related to the nonmyeloablative lymphodepletion preconditioning regimen.The trial is assessing the use of LN-145 in patients who have progressed on or after chemotherapy and anti-PD-1 therapy for advanced (unresectable or metastatic) NSCLC without EGFR, ROS, or ALK genomic mutations and who had received at least 1 line of an FDA-approved targeted therapy if indicated by other actionable tumor mutations.Iovance announced that it will pause enrollment and the LN-145 TIL treatment regimen for new patients in IOV-LUN-202 during the clinical hold time. Patients previously treated with LN-145 in the trial will continue to undergo monitoring and will be followed according to the trial protocol. Patients who have already undergone tumor resection will continue to receive the LN-145 TIL treatment regimen with additional precautions and risk mitigations.&ldquo;Iovance remains dedicated to addressing a significant unmet medical need for patients with advanced NSCLC who have poor prognosis following disease progression and limited treatment options. We will work with the FDA to safely resume enrollment in the IOV-LUN-202 trial as soon as possible,&rdquo; said Friedrich Graf Finckenstein, MD, chief medical officer of Iovance.

Jordana Jampel

Systematic Review of Suicide, Self-Harm Potentiality in GLP-1 RA Trials

Metabolic Disorders

Connie Rhee, MD

Joel M. Topf, MD, FACP

CKD Management and Cognition

NKF Spring Clinical Meetings 2025

Bradley Marder, MD

Gout Studies: Transplant Waitlisting and Bone Erosion

Latest News

Iovance Biotherapeutics Announces Pause of NSCLC Trial

Non-Small Cell Lung Cancer

Iovance Biotherapeutics has announced a clinical program update for LN-145 tumor-infiltrating lymphocyte therapy in the treatment of non-small cell lung cancer.

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe